rituximab + zanubrutinib + lenalidomide

This is a combination regimen of three drugs—rituximab, zanubrutinib, and lenalidomide—used primarily in the treatment of B-cell lymphomas such as diffuse large B-cell lymphoma (DLBCL), primary or secondary central nervous system lymphoma (CNS lymphoma), and B-cell prolymphocytic leukemia (B-PLL). - **Rituximab** is a monoclonal antibody targeting CD20 on B cells, leading to their depletion via immune-mediated mechanisms. - **Zanubrutinib** is a small molecule Bruton’s tyrosine kinase (BTK) inhibitor that blocks B cell receptor signaling, inhibiting malignant B cell proliferation and survival. - **Lenalidomide** is an immunomodulatory agent that enhances T-cell and natural killer cell function, inhibits angiogenesis, induces apoptosis in tumor cells, and can enhance the efficacy of monoclonal antibodies like rituximab through increased antibody-dependent cellular cytotoxicity. The combination has shown efficacy in unfit or elderly patients with DLBCL who are not candidates for standard chemotherapy regimens[2][3][5][9]. It has also been explored for relapsed/refractory CNS lymphoma[5] and TP53-mutated B-PLL[3]. The regimen may offer a chemo-free alternative with manageable toxicity but requires monitoring for hematological adverse events such as neutropenia and thrombocytopenia as well as bleeding risks due to platelet inhibition by the combination[2].

Other names

ZR2ZR-2ZR 2zanubrutinib-lenalidomide-rituximab